Another gene alteration that was found in this patient’s tumor – PBRM1 inactivation – may predict the benefit of ICI targeting PD-1, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and previous antiangiogenic therapy (37). Here, PDCD1 is linked to neoplasm.